Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. The company was incorporated in 2007 and is headquartered in Solana Beach, California.
Earnings for Organovo Holdings, Inc. (ONVO)
Earnings in 2023 (TTM): $-14,669,000
According to Organovo Holdings, Inc.'s latest financial reports the company's current earnings (TTM) are $-14,669,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Organovo Holdings, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-14,669,000 | $-14,671,000 |
| 2022 | $-17,257,000 | $-17,259,000 |
| 2021 | $-11,446,000 | $-11,448,000 |
| 2020 | $-16,824,000 | $-16,826,000 |
| 2019 | $-18,708,000 | $-18,710,000 |
| 2018 | $-26,632,000 | $-26,635,000 |
| 2017 | $-34,801,000 | $-34,803,000 |
| 2016 | $-38,424,000 | $-38,447,000 |
| 2015 | $-38,572,000 | $-38,575,000 |
| 2014 | $-30,082,000 | $-30,082,000 |
| 2013 | $-25,848,000 | $-25,848,000 |
| 2012 | $-43,553,000 | $-43,553,000 |
| 2010 | $-147,817 | $-147,817 |